Eupraxia Pharmaceuticals (EPRX) Investor presentation summary

Product overview and clinical integration

• EP-104GI is a novel, long-acting fluticasone propionate formulation for eosinophilic esophagitis (EoE), administered once yearly via submucosal injection during routine endoscopy.

• Administration aligns with standard endoscopic procedures, using established injection techniques familiar to gastroenterologists.

• The injection pattern covers the full esophagus with 20 paired injections spaced 2cm apart.

• Integration into GI care is seamless, requiring no new equipment or significant workflow changes.

Endoscopy practice and logistics

• Upper endoscopies are common, high-volume outpatient procedures with mature infrastructure and standardized protocols.

• Most endoscopies in the US are performed in ambulatory surgery centers (ASCs) or hospital outpatient departments (HOPDs), with ASCs handling the majority of routine cases.

• Endoscopy suites are accustomed to handling a mix of procedures and patient types, with flexible scheduling to absorb minor delays.

• Submucosal injections are routine, and staff are already trained for similar procedures.

Financial and operational impact

• EP-104GI administration enables upgraded CPT coding, increasing reimbursement for both physicians and facilities.

• The buy-and-bill model offers additional revenue, with EP-104GI expected to qualify for a unique J-code and attractive margins, especially for commercial payers.

• No incremental equipment or overhead costs are anticipated, as existing infrastructure and staff can accommodate the new therapy.

• Minimal impact on staffing or throughput, as the additional procedure time is absorbed within standard scheduling buffers.